JP2019512492A5 - - Google Patents

Download PDF

Info

Publication number
JP2019512492A5
JP2019512492A5 JP2018548056A JP2018548056A JP2019512492A5 JP 2019512492 A5 JP2019512492 A5 JP 2019512492A5 JP 2018548056 A JP2018548056 A JP 2018548056A JP 2018548056 A JP2018548056 A JP 2018548056A JP 2019512492 A5 JP2019512492 A5 JP 2019512492A5
Authority
JP
Japan
Prior art keywords
formula
optionally substituted
alkyl
compound
drug linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018548056A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512492A (ja
JP7073266B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/024148 external-priority patent/WO2017165851A1/en
Publication of JP2019512492A publication Critical patent/JP2019512492A/ja
Publication of JP2019512492A5 publication Critical patent/JP2019512492A5/ja
Priority to JP2022064462A priority Critical patent/JP2022082777A/ja
Application granted granted Critical
Publication of JP7073266B2 publication Critical patent/JP7073266B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018548056A 2016-03-25 2017-03-24 Peg化薬物リンカー及びその中間体を調製するためのプロセス Active JP7073266B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022064462A JP2022082777A (ja) 2016-03-25 2022-04-08 Peg化薬物リンカー及びその中間体を調製するためのプロセス

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662313460P 2016-03-25 2016-03-25
US62/313,460 2016-03-25
PCT/US2017/024148 WO2017165851A1 (en) 2016-03-25 2017-03-24 Process for the preparation of pegylated drug-linkers and intermediates thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020053136A Division JP2020100669A (ja) 2016-03-25 2020-03-24 Peg化薬物リンカー及びその中間体を調製するためのプロセス
JP2022064462A Division JP2022082777A (ja) 2016-03-25 2022-04-08 Peg化薬物リンカー及びその中間体を調製するためのプロセス

Publications (3)

Publication Number Publication Date
JP2019512492A JP2019512492A (ja) 2019-05-16
JP2019512492A5 true JP2019512492A5 (enExample) 2020-05-07
JP7073266B2 JP7073266B2 (ja) 2022-05-23

Family

ID=59900804

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018548056A Active JP7073266B2 (ja) 2016-03-25 2017-03-24 Peg化薬物リンカー及びその中間体を調製するためのプロセス
JP2020053136A Pending JP2020100669A (ja) 2016-03-25 2020-03-24 Peg化薬物リンカー及びその中間体を調製するためのプロセス
JP2022064462A Pending JP2022082777A (ja) 2016-03-25 2022-04-08 Peg化薬物リンカー及びその中間体を調製するためのプロセス
JP2023092604A Pending JP2023106627A (ja) 2016-03-25 2023-06-05 Peg化薬物リンカー及びその中間体を調製するためのプロセス

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020053136A Pending JP2020100669A (ja) 2016-03-25 2020-03-24 Peg化薬物リンカー及びその中間体を調製するためのプロセス
JP2022064462A Pending JP2022082777A (ja) 2016-03-25 2022-04-08 Peg化薬物リンカー及びその中間体を調製するためのプロセス
JP2023092604A Pending JP2023106627A (ja) 2016-03-25 2023-06-05 Peg化薬物リンカー及びその中間体を調製するためのプロセス

Country Status (15)

Country Link
US (2) US11844839B2 (enExample)
EP (1) EP3433278A4 (enExample)
JP (4) JP7073266B2 (enExample)
KR (2) KR102626498B1 (enExample)
CN (1) CN109843919A (enExample)
AU (1) AU2017237186B2 (enExample)
BR (1) BR112018069273A2 (enExample)
CA (1) CA3017527A1 (enExample)
EA (1) EA201892040A1 (enExample)
IL (2) IL261759B (enExample)
MA (1) MA43835A (enExample)
SG (1) SG11201807827VA (enExample)
TW (2) TWI790996B (enExample)
UA (1) UA125510C2 (enExample)
WO (1) WO2017165851A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3433278A4 (en) * 2016-03-25 2019-11-06 Seattle Genetics, Inc. METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF
WO2018075692A2 (en) 2016-10-19 2018-04-26 Invenra Inc. Antibody constructs
JP7330101B2 (ja) 2016-11-08 2023-08-21 レゲネロン ファーマシューティカルス,インコーポレーテッド ステロイド及びそのタンパク質コンジュゲート
CN110291107B (zh) 2016-12-22 2023-05-05 卡坦扎罗麦格纳格拉西亚大学 靶向cd43的独特唾液酸糖基化的癌症相关表位的单克隆抗体
CN110430901B (zh) * 2017-03-24 2024-08-16 西雅图基因公司 制备葡糖苷酸药物-接头及其中间体的方法
US11491237B2 (en) 2017-05-18 2022-11-08 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
MX2020004691A (es) * 2017-11-07 2020-08-20 Regeneron Pharma Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
BR112020013492A2 (pt) 2018-01-08 2020-12-08 Regeneron Pharmaceuticals, Inc. Esteroides e conjugados de anticorpo dos mesmos
KR20210008008A (ko) 2018-05-09 2021-01-20 리제너론 파마슈티칼스 인코포레이티드 항-msr1 항체 및 이의 사용 방법
SG11202011984UA (en) 2018-06-05 2020-12-30 King S College London Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
KR20230158005A (ko) 2021-03-18 2023-11-17 씨젠 인크. 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
WO2023163536A1 (ko) * 2022-02-25 2023-08-31 앱티스 주식회사 신규 항체 약물 접합체
AU2023298568A1 (en) 2022-06-30 2025-01-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
WO2024108053A1 (en) 2022-11-17 2024-05-23 Sanofi Ceacam5 antibody-drug conjugates and methods of use thereof
AU2024256916A1 (en) 2023-04-18 2025-12-04 Astrazeneca Ab Conjugates comprising cleavable linkers
AR133124A1 (es) 2023-06-29 2025-08-27 Beigene Switzerland Gmbh Conjugados bioactivos, método de preparación y uso de estos

Family Cites Families (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8504461A1 (es) 1982-04-12 1985-04-16 Hybritech Inc Un procedimiento para obtener un polidoma.
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
FI102355B (fi) 1988-02-11 1998-11-30 Squibb Bristol Myers Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjug aattien valmistamiseksi
US5851527A (en) 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
FR2676058B1 (fr) 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US6569834B1 (en) 1992-12-03 2003-05-27 George R. Pettit Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
DE69425439D1 (de) * 1993-09-29 2000-09-07 Nissin Food Products Ltd In stellung 21 substituierte steroide
WO1995009864A1 (en) 1993-10-01 1995-04-13 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivative
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
JP2763020B2 (ja) 1995-04-27 1998-06-11 日本電気株式会社 半導体パッケージ及び半導体装置
DE19516717A1 (de) 1995-05-06 1996-11-07 Basf Ag Verfahren zur Herstellung von Diarylethanen
US5756593A (en) 1995-05-15 1998-05-26 Enzon, Inc. Method of preparing polyalkyene oxide carboxylic acids
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
DK0871490T3 (da) 1995-12-22 2003-07-07 Bristol Myers Squibb Co Forgrenede hydrazonlinkere
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
AU717020B2 (en) 1996-05-03 2000-03-16 Immunomedics Inc. Targeted combination immunotherapy of cancer
US7011812B1 (en) 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
JP4410852B2 (ja) 1996-08-02 2010-02-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 単一の共有結合n末端水溶性ポリマーを有するポリペプチド
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
JP2002513402A (ja) 1997-02-25 2002-05-08 アリゾナ ボード オブ リーゼンツ 細胞増殖抑制性の鎖状および環状デプシペプチドであるドラスタチン16、ドラスタチン17およびドラスタチン18の単離と構造決定
JP2002505574A (ja) 1997-04-30 2002-02-19 エンゾン,インコーポレイテッド ポリアルキレンオキシド修飾された単鎖ポリペプチド
US20040009166A1 (en) 1997-04-30 2004-01-15 Filpula David R. Single chain antigen-binding polypeptides for polymer conjugation
AU1417999A (en) 1997-11-21 1999-06-15 Human Genome Sciences, Inc. Chemokine alpha-5
GB2332539B (en) 1997-12-17 2003-04-23 Fujitsu Ltd Memory access methods and devices for use with random access memories
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US7060479B2 (en) 1999-12-08 2006-06-13 Serono Genetics Institute, S.A. Full-length human cDNAs encoding potentially secreted proteins
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6214330B1 (en) 1998-07-13 2001-04-10 Enzon, Inc. Coumarin and related aromatic-based polymeric prodrugs
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US6323135B1 (en) 1998-12-09 2001-11-27 Advanced Micro Devices, Inc. Method of forming reliable capped copper interconnects/with high etch selectivity to capping layer
JP2000230000A (ja) 1999-02-08 2000-08-22 Hokkaido Univ 一酸化窒素代謝物−ポリオキシアルキレン−ヘモグロビン結合体
WO2001062827A2 (en) 2000-02-22 2001-08-30 Shearwater Corporation N-maleimidyl polymer derivatives
US6777387B2 (en) 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
AU2001272017A1 (en) 2000-06-20 2002-01-02 Immunomedics Inc. Targeted combination immunotherapy of cancer and infectious diseases
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
CN100406065C (zh) 2000-12-01 2008-07-30 细胞工厂治疗公司 糖基化/半乳糖基化肽、双官能接头和核苷酸单体/多聚体的缀合物以及相关的组合物和使用方法
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
JP4179771B2 (ja) 2001-06-25 2008-11-12 株式会社デンソー 自動車の乗員保護装置
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
CA2466027C (en) 2001-11-07 2013-01-08 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
BR0306808A (pt) 2002-01-09 2005-08-30 Medarex Inc Anticorpos monoclonais humanos contra cd30
WO2003070823A2 (en) 2002-02-20 2003-08-28 The General Hospital Corporation Conjugates comprising a biodegradable polymer and uses therefor
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
GB0218518D0 (en) 2002-03-22 2002-09-18 Aventis Pharma Inc Human deubiquitinating protease gene on chromosome 7 and its murine ortholog
WO2003086312A2 (en) 2002-04-12 2003-10-23 A & D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and cancer chemotherapeutic agents/boron neutron capture therapy agents, and uses thereof
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
US7413738B2 (en) 2002-08-13 2008-08-19 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on biodegradable linkers
US7462687B2 (en) 2002-11-12 2008-12-09 Enzon Pharmaceuticals, Inc. Prodrugs of vancomycin with hydrolysis resistant polymer linkages
US7273845B2 (en) 2002-11-12 2007-09-25 Enzon Pharmaceuticals, Inc. Polymeric prodrugs of vancomycin
DE10254439A1 (de) 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysine, Herstellungsverfahren und Tubulysin-Mittel
US7888536B2 (en) 2004-02-13 2011-02-15 Quanta Biodesign, Ltd. Selective and specific preparation of discrete PEG compounds
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
KR20060015505A (ko) 2003-04-13 2006-02-17 엔존 파마슈티컬즈, 인코포레이티드 올리고뉴클레오타이드 전구약물
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
AU2004247015B2 (en) 2003-05-14 2010-12-16 Immunogen, Inc. Drug conjugate composition
ES2456325T3 (es) 2003-11-06 2014-04-22 Seattle Genetics, Inc. Compuestos de monometilvalina capaces de conjugación con ligandos
US20060003412A1 (en) 2003-12-08 2006-01-05 Xencor, Inc. Protein engineering with analogous contact environments
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
ES2741524T3 (es) 2004-03-23 2020-02-11 Ascendis Pharma Gmbh Profármaco polimérico con un enlazador autoinmolador
EP1747021B1 (en) 2004-05-19 2015-09-09 E. R. Squibb & Sons, L.L.C. Self-immolative linkers and drug conjugates
US8288352B2 (en) 2004-11-12 2012-10-16 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
US20070134243A1 (en) 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
US7947839B2 (en) 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
JP2008537673A (ja) 2005-01-31 2008-09-25 ジェネンテック・インコーポレーテッド 抗ephb2抗体とその使用方法
WO2006088248A1 (ja) 2005-02-18 2006-08-24 Nof Corporation ポリオキシアルキレン誘導体
ES2477765T3 (es) 2005-04-19 2014-07-17 Seattle Genetics, Inc. Agentes de unión al anti-cd70 humanizado y usos de los mismos
US8132476B2 (en) 2005-06-20 2012-03-13 Hy-Energy, Llc Method and apparatus for handling small quantities of fluids
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
DK1912671T3 (da) 2005-07-18 2017-11-27 Seattle Genetics Inc Beta-glucuronid-linker-lægemiddelkonjugater
WO2007080114A2 (en) 2006-01-11 2007-07-19 Biotech Igg Ab Macromolecule conjugate
SI1813614T1 (sl) 2006-01-25 2012-01-31 Sanofi 174 Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2007103288A2 (en) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
US8257706B2 (en) 2006-08-25 2012-09-04 Seattle Genetics, Inc. CD30 binding agents and uses thereof
EP2076257A4 (en) 2006-09-15 2014-04-16 Belrose Pharma Inc POLYMER CONJUGATES WITH POSITIVELY LOADED PARTS
US8367065B2 (en) 2006-09-15 2013-02-05 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
WO2008034120A2 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Lysine-based polymeric linkers
JP2010503708A (ja) 2006-09-15 2010-02-04 エンゾン ファーマスーティカルズ インコーポレイテッド 多官能性リンカーを含む標的化ポリマープロドラッグ
KR101309948B1 (ko) 2006-11-10 2013-09-23 씨오브이엑스 테크놀로지스 아일랜드 리미티드 혈관 신생 억제 화합물
EP2609932B1 (en) 2006-12-01 2022-02-02 Seagen Inc. Variant target binding agents and uses thereof
US7884869B2 (en) 2007-04-30 2011-02-08 Motorola Mobility, Inc. Assignment of pixel element exposure times in digital camera modules and mobile communication devices
RU2523909C2 (ru) 2007-06-25 2014-07-27 Эндосайт, Инк. Конъюгаты, содержащие гидрофильные спейсеры линкеров
CA2693645A1 (en) 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery systems containing an aromatic allylic acid
CA2693616A1 (en) 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery system containing a multi-substituted aromatic moiety
US20110263650A1 (en) 2007-07-20 2011-10-27 Helmholtz-Zentrum Für Infektions-Forschung Gmbh Tubulysin D Analogues
JP2010536986A (ja) 2007-08-20 2010-12-02 エンゾン ファーマシューティカルズ,インコーポレーテッド ピリジルジスルフィド部分を含有するポリマーリンカー
US7968687B2 (en) 2007-10-19 2011-06-28 Seattle Genetics, Inc. CD19 binding agents and uses thereof
US8609105B2 (en) 2008-03-18 2013-12-17 Seattle Genetics, Inc. Auristatin drug linker conjugates
EP2174947A1 (en) 2008-09-25 2010-04-14 Universität des Saarlandes Bioactive pre-tubulysins and use thereof
CA2738807A1 (en) 2008-10-21 2010-04-29 Enzon Pharmaceuticals, Inc. Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
EP2376110B1 (en) 2009-01-09 2019-03-13 Seattle Genetics, Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
ES2464123T3 (es) 2009-01-12 2014-05-30 University Of Washington Procedimiento para la 2-sulfatación de glucósidos
CN105198908B (zh) 2009-02-05 2019-12-24 伊缪诺金公司 新型苯并二氮杂*衍生物
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
EP2480230A4 (en) 2009-09-24 2015-06-10 Seattle Genetics Inc DR5 Ligand-HEILMITTELKONJUGATE
KR20120080611A (ko) 2009-10-06 2012-07-17 이뮤노젠 아이엔씨 효능 있는 접합체 및 친수성 링커
WO2011057805A1 (en) 2009-11-12 2011-05-19 R&D Biopharmaceuticals Gmbh Tubulin inhibitors
EP2322537A1 (en) 2009-11-12 2011-05-18 R & D Biopharmaceuticals Gmbh Tubulin inhibitors
EP2509421B1 (en) 2009-12-10 2020-02-05 Cedars-Sinai Medical Center Drug delivery of temozolomide for systemic based treatment of cancer
US8609092B2 (en) 2010-02-08 2013-12-17 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
PT2542576T (pt) 2010-03-02 2016-07-14 Seattle Genetics Inc Métodos para rastreio de anticorpos
JP2013528665A (ja) 2010-03-26 2013-07-11 メルサナ セラピューティックス, インコーポレイテッド ポリヌクレオチドの送達のための修飾ポリマー、その製造方法、およびその使用方法
ES2623057T3 (es) 2010-04-15 2017-07-10 Medimmune Limited Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas
CN102933236B (zh) 2010-04-15 2014-10-08 斯皮罗根有限公司 吡咯并苯二氮卓类及其结合物
CN103068405A (zh) 2010-04-15 2013-04-24 西雅图基因公司 靶向吡咯并苯并二氮杂卓结合物
WO2011130599A1 (en) 2010-04-16 2011-10-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates of adenine nucleoside analogs
EP2409983A1 (en) 2010-07-19 2012-01-25 Leibniz-Institut für Pflanzenbiochemie (IPB) Tubulysin analogues
KR101993921B1 (ko) 2010-12-06 2019-06-28 시애틀 지네틱스, 인크. Liv-1에 대한 인간화 항체 및 이의 암을 치료하기 위한 용도
PT2675480T (pt) 2011-02-15 2019-04-15 Immunogen Inc Métodos para preparação de conjugados
WO2012113847A1 (en) 2011-02-25 2012-08-30 Lonza Ltd Branched linker for protein drug conjugates
DK2714684T3 (en) 2011-05-27 2018-11-26 Ambrx Inc COMPOSITIONS CONTAINING, PROCEDURE INVOLVING, AND APPLICATIONS OF NON-NATURAL AMINO ACID-BONDED DOLASTATIN DERIVATIVES
US20130052130A1 (en) 2011-08-30 2013-02-28 University Of Washington Branched Discreet PEG Constructs
CN103987718A (zh) 2011-09-20 2014-08-13 斯皮罗根有限公司 作为非对称二聚体pbd化合物用于内含在靶向结合物中的吡咯并苯并二氮杂卓
CA2850375C (en) 2011-10-14 2019-07-02 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
CN103998450B (zh) 2011-10-14 2017-03-08 麦迪穆有限责任公司 吡咯并苯并二氮杂卓
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
EA031069B1 (ru) 2012-02-17 2018-11-30 Сиэтл Дженетикс, Инк. АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αVβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
US20130225789A1 (en) 2012-02-29 2013-08-29 Yi Sun Polyethylene Glycol Having Hetero Multiple Functional Groups
EP2850201A4 (en) 2012-05-11 2016-08-31 Alexander Krantz Site-specific labeling and targeted administration of proteins for the treatment of cancer
JP6280103B2 (ja) 2012-05-15 2018-02-14 ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. 薬物コンジュゲート、コンジュゲーション方法およびその使用
KR102144069B1 (ko) 2012-05-15 2020-08-13 시애틀 지네틱스, 인크. 자가-안정화 링커 접합체
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
US9650331B2 (en) 2012-06-18 2017-05-16 Polytherics Limited Conjugation reagents
ES2782248T3 (es) 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
IN2015DN02349A (enExample) 2012-10-24 2015-08-28 Polytherics Ltd
NZ710746A (en) 2013-03-13 2018-11-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
BR112015021134A2 (pt) * 2013-03-15 2017-10-10 Novartis Ag conjugados de fármaco e anticorpo
US9430462B2 (en) 2013-07-30 2016-08-30 Edanz Group Ltd. Guided article authorship
JP6747971B2 (ja) 2013-10-15 2020-08-26 シアトル ジェネティックス, インコーポレイテッド 改善されたリガンド−薬物コンジュゲート薬物動態のためのpeg化薬物−リンカー
IL290330B2 (en) * 2013-12-19 2023-09-01 Seagen Inc Methylene carbamate binders for use with drug-targeting conjugates
AU2015315007C1 (en) 2014-09-11 2021-06-03 Seagen Inc. Targeted delivery of tertiary amine-containing drug substances
GB201416960D0 (en) 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
MX382582B (es) 2015-03-18 2025-03-13 Seagen Inc Anticuerpos contra cúmulo de diferenciación 48 (cd48) y sus conjugados.
EP3433278A4 (en) * 2016-03-25 2019-11-06 Seattle Genetics, Inc. METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF
CN109562152B (zh) 2016-08-09 2024-04-02 西雅图基因公司 含有具有改善的生理化学性质的自稳定性接头的药物缀合物
CN110430901B (zh) 2017-03-24 2024-08-16 西雅图基因公司 制备葡糖苷酸药物-接头及其中间体的方法

Similar Documents

Publication Publication Date Title
JP2019512492A5 (enExample)
JP2019512492A (ja) Peg化薬物リンカー及びその中間体を調製するためのプロセス
JP2009501800A5 (enExample)
JP2016153410A5 (enExample)
US20200392108A1 (en) Antibody-drug conjugates and related compounds, compositions and methods
JP7550768B2 (ja) 抗体-薬物コンジュゲート用のグリコシド含有ペプチドリンカー
JP2020531471A5 (enExample)
JP2011500725A5 (enExample)
RU2016139340A (ru) Коньюгаты "антитело - лекарственное средство" с высокой лекарственной нагрузкой
JP2006507265A5 (enExample)
CN104870021A (zh) 药物-蛋白质缀合物
EP3525826B1 (en) Non-linear self-immolative linkers and conjugates thereof
CY1112086T1 (el) Συνδυασμος γλυκοπυρρολικου αλατος και ενος αγωνιστη βητα2 αδρενεργικων υποδοχεων
JP2014528480A5 (enExample)
RU2016129894A (ru) Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
RU2015156499A (ru) Конъюгаты антитела с лекарственным средством
JP2008524338A5 (enExample)
JP2018058822A5 (enExample)
JPWO2020028610A5 (enExample)
JPWO2020028608A5 (enExample)
JP2021503915A5 (enExample)
JP2023517939A (ja) オーロラaキナーゼの分解のためのタンパク質分解誘導キメラ分子(protac)
JP2020532565A5 (enExample)
JPWO2019161174A5 (enExample)
RU2017103462A (ru) Материалы и способы, связанные с линкерами для применения в конъюгатах лекарственного средства и белка